Nashville、TNにおける転移性癌の臨床試験
Nashvilleとその周辺地域（約30マイル以内）の拠点で、転移性癌に関する70件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
被験者募集中第1/2相
- Avenzo Therapeutics Recruiting Site, Nashville
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
被験者募集中第3相
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology, Nashville
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
被験者募集中第2相
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Tennessee Oncology, Nashville
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
被験者募集中第1相
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology PLLC, Nashville
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
被験者募集中第1/2相
- Sarah Cannon Research Institute, Nashville
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
被験者募集中第1相
- Sarah Cannon Research Institute (SCRI), Nashville
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
被験者募集中第1相
- Sarah Cannon Research Institute (SCRI), Nashville
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
被験者募集中第1相
- SCRI Oncology Partners, Nashville
A Study of ASP3082 in Adults With Advanced Solid Tumors
被験者募集中第1相
- Vanderbilt University Medical Center, Nashville
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
被験者募集中第2/3相
- Henry-Joyce Cancer Clinic, Nashville
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
被験者募集中第1相
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
被験者募集中第3相
- Henry-Joyce Cancer Clinic, Nashville
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
被験者募集中第1相
- Sarah Cannon Research Institute, Nashville
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
被験者募集中第3相
- Research Site, Nashville
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
被験者募集中第2/3相
- Henry-Joyce Cancer Clinic, Nashville
A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors
被験者募集中第1相
- SCRI Oncology Partners, Nashville
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
被験者募集中第3相
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, PLLC-Elliston Place Plaza Medical Oncology &Hematology, Nashville
- Tennessee Oncology, PLLC - Saint Thomas West, Nashville
- 他3件
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
被験者募集中第1/2相
- Sarah Cannon Research Institute, Nashville
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
被験者募集中第3相
- Vanderbilt University Medical Center, Nashville
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
被験者募集中第3相
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, Nashville
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
被験者募集中第3相
- Sarah Cannon Research Institute SCRI, Nashville
- Nashville General Hospital, Nashville
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
被験者募集中第1/2相
- Sarah Cannon Research Institue, Nashville
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
被験者募集中第1相
- Tennessee Oncology PLLC, Nashville
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
被験者募集中第1/2相
- Tennessee Oncology, PLLC, Nashville
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
被験者募集中第1/2相
- Sarah Cannon Research Institute, Nashville
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
被験者募集中第1/2相
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, PLLC- Elliston Place Plaza, Nashville
- 他11件
Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
被験者募集中第1/2相
- SCRI Oncology Partners, Nashville
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- Clinical Study Site, Nashville
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
被験者募集中第1相
- Sarah Cannon Research Center, Nashville
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
被験者募集中第3相
- Research Site, Nashville
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
被験者募集中第3相
- Tennessee Oncology, Nashville
- USO - US Oncology Research Network, Nashville
NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies
被験者募集中第1相
- Sarah Cannon Research Institute, Nashville
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
被験者募集中第2相
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
被験者募集中第1/2相
- Sarah Cannon Research Institute - Tennessee Oncology, Nashville
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
被験者募集中第1相
- Sarah Cannon Research Institute-Tennessee Oncology, Nashville
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
被験者募集中第2相
- Vanderbilt-Ingram Cancer Center, Nashville
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
被験者募集中第1相
- Sarah Cannon and HCA Research Institute, Nashville
- Tennessee Oncology, Nashville
- Vanderbilt University Medical Center, Nashville
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
被験者募集中第2相
- Research Site, Nashville
FOG-001 in Locally Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- Sarah Cannon Research Institute, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
被験者募集中第1/2相
- Vanderbilt University/Ingram Cancer Center, Nashville
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- SCRI Oncology Partners, Nashville
- Vanderbilt Medical Center, Nashville
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
被験者募集中第3相
- Research Site, Nashville
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Investigative Site #102, Nashville
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
被験者募集中第1相
- SCRI Oncology Partners, Nashville
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Sara Cannon Research Institute Tennessee, Nashville
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Exelixis Clinical Site #3, Nashville
A Study of LY4175408 in Participants With Advanced Cancer
被験者募集中第1相
- Sarah Cannon Research Institute, Nashville
CT-95 in Advanced Cancers Associated With Mesothelin Expression
被験者募集中第1相
- Context Investigational Site, Nashville
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
被験者募集中第1相
- Research Site, Nashville
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
被験者募集中第1相
- Sarah Cannon Research Institute, Nashville
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
被験者募集中第1相
- Vanderbilt University Medical Center, Nashville
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
被験者募集中第1/2相
- Sarah Cannon, Nashville
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
被験者募集中第1/2相
- SCRI Oncology Partners, Nashville
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
被験者募集中第1/2相
- Sarah Cannon Research Institute, Nashville
Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
被験者募集中早期第1相
- Vanderbilt University Medical Center, Nashville
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
被験者募集中第1/2相
- SCRI Oncology Partners, Nashville
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
被験者募集中第2/3相
- Sarah Cannon Research Institute, Nashville
- Vanderbilt Ingram Cancer Center (Henry-Joyce Cancer Clinic), Nashville
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
被験者募集中第1相
- SCRI Oncology Partners, Nashville
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
被験者募集中第1相
- SCRI Oncology Partners, Nashville
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
被験者募集中第1相
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
- Vanderbilt University Medical Center, Nashville
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
被験者募集中第3相
- Vanderbilt University Medical Center, Nashville
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
被験者募集中第1相
- Urology Associates PC, Nashville
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
被験者募集中第1相
- Vanderbilt-Ingram Cancer Center, Nashville
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
被験者募集中第1相
- SCRI Oncology Partners, Nashville
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
被験者募集中第1相
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
被験者募集中第1/2相
- SCRI Oncology Partners, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Nashville
ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)
被験者募集中第1相
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
他の都市における転移性癌の試験
- Houston, TX104件の研究
- New York City, NY93件の研究
- Boston, MA63件の研究
- Los Angeles, CA57件の研究
- St. Louis, MO54件の研究
- Arlington, VA53件の研究
- Philadelphia, PA46件の研究
- Chicago, IL45件の研究
- San Antonio, TX44件の研究
- Washington, DC43件の研究
- Dallas, TX42件の研究
- Seattle, WA39件の研究
Nashvilleにおける他の研究
- 非小細胞肺癌97件の研究
- 乳がん81件の研究
- 大腸癌69件の研究
- がん（全種類）65件の研究
- 卵巣がん49件の研究
- 前立腺がん43件の研究
- 肺がん40件の研究
- 頭頸部扁平上皮癌39件の研究
- 膵臓がん39件の研究
- 子宮内膜がん38件の研究
- 悪性黒色腫33件の研究
- 多発性骨髄腫32件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。